PHGE
BiomX·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Gap Up
Significant Net Income Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PHGE
Biomx Inc.
A clinical-stage microbiome company that develops therapies to target and destroy harmful bacteria in chronic diseases
22 Einstein St., Floor 4, Ness Ziona, Israel 7414003
--
BiomX Inc. was incorporated under the laws of the State of Delaware on November 1, 2017. On October 28, 2019, the company merged with BiomX Ltd., then changed its name to BiomX Inc. The company is developing natural and engineered phage mixtures designed to target and eliminate harmful bacteria in chronic diseases, and is currently focusing on cystic fibrosis and, to a lesser extent, atopic dermatitis. The company discovers and validates proprietary bacterial targets and customizes phage compositions for these targets.
Earnings Call
Q2/2025
Estimate EPS-0.19
Actual EPS-0.19
Estimate Revenue--
Actual Revenue0
BiomX's Q2 2025 Earnings Call: Unraveling Contradictions in BX211 and BX004 Development Strategies
Aug 13,2025 11:56
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PHGE has released its 2025 Q3 earnings. EPS was reported at -0.29, versus the expected -0.32, beating expectations. The chart below visualizes how PHGE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
